{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:50:44Z","timestamp":1790855444609,"version":"4.1.0"},"reference-count":23,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>Patients with a compromised immune system are at risk for converting from latent tuberculosis infection (LTBI) to active tuberculosis (TB) infection. Multiple sclerosis (MS) therapies may put individuals with LTBI at higher risk of TB.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Patients at the Beth Israel Deaconess Medical Center MS Clinic were screened for TB as part of routine testing with the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay (Cellestis Ltd) from 2013 to 2017. Patients were tested either before or during immunomodulatory therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Four of 222 patients (1.8%; 95% CI, 0.1%\u20133.6%) had positive QFT-GIT results; three patients had risk factors for TB, having emigrated from TB-endemic countries or worked in the health care industry. Twenty-eight of 222 patients (12.6%) had an indeterminate assay result, and 75.0% of these occurred in patients taking dimethyl fumarate. Fingolimod, natalizumab, or anti-CD20 treatments showed 0% to 7.7% indeterminate results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>The prevalence of LTBI was 1.8% in the Beth Israel Deaconess Medical Center MS Clinic. Not all LTBI cases were associated with known risk factors for TB. Screening for LTBI before starting immunosuppressive agents for MS could help prevent activation of TB. Dimethyl fumarate use is associated with indeterminate QFT-GIT results, possibly due to functional effects on lymphocytes and levels of cytokines, such as interferon gamma. In contrast, fingolimod use was rarely associated with indeterminate QFT-GIT results despite a high rate of lymphopenia in virtually all patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.7224\/1537-2073.2019-015","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T16:54:23Z","timestamp":1586883263000},"page":"26-30","source":"Crossref","is-referenced-by-count":17,"title":["Prevalence of Latent Tuberculosis in the Multiple Sclerosis Clinic and Effect of Multiple Sclerosis Treatment on Tuberculosis Testing"],"prefix":"10.7224","volume":"23","author":[{"given":"Andrew J.","family":"Bouley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursela","family":"Baber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Egnor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soleil","family":"Samaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Sloane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4242","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"key":"2021022417494907600_i1537-2073-23-1-26-b1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1164\/rccm.201508-1683OC","article-title":"The prevalence of latent tuberculosis infection in the United States","volume":"194","author":"Mancuso","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"2021022417494907600_i1537-2073-23-1-26-b2","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3201\/eid2410.180716","article-title":"Simple estimates for local prevalence of latent tuberculosis infection, United States, 2011\u20132015","volume":"24","author":"Haddad","year":"2018","journal-title":"Emerg Infect Dis."},{"key":"2021022417494907600_i1537-2073-23-1-26-b3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/acn3.491","article-title":"Infectious risk stratification in multiple sclerosis patients receiving immunotherapy","volume":"4","author":"Graf","year":"2017","journal-title":"Ann Clin Transl Neurol."},{"key":"2021022417494907600_i1537-2073-23-1-26-b4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14745\/ccdr.v43i34a01","article-title":"Latent tuberculosis infection: an overview","volume":"43","author":"Kiazyk","year":"2017","journal-title":"Can Commun Dis Rep."},{"key":"2021022417494907600_i1537-2073-23-1-26-b5","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis."},{"key":"2021022417494907600_i1537-2073-23-1-26-b6","first-page":"4","article-title":"Latent Mycobacterium tuberculosis infection and interferon-gamma release assays","author":"Pai","year":"2016","journal-title":"Microbiol Spectr."},{"key":"2021022417494907600_i1537-2073-23-1-26-b7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fneur.2018.00005","article-title":"Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis","volume":"9","author":"Mills","year":"2018","journal-title":"Front Neurol."},{"key":"2021022417494907600_i1537-2073-23-1-26-b8","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1212\/NXI.0000000000000183","article-title":"Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis","volume":"3","author":"Gross","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"2021022417494907600_i1537-2073-23-1-26-b9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12974-015-0460-z","article-title":"Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation","volume":"12","author":"Mazzola","year":"2015","journal-title":"J Neuroinflammation."},{"key":"2021022417494907600_i1537-2073-23-1-26-b10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00430-016-0482-x","article-title":"Effect of teriflunomide on QuantiFERON-TB Gold results","volume":"206","author":"Bua","year":"2017","journal-title":"Med Microbiol Immunol."},{"key":"2021022417494907600_i1537-2073-23-1-26-b11","doi-asserted-by":"crossref","first-page":"e52208","DOI":"10.1371\/journal.pone.0052208","article-title":"Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis","volume":"7","author":"Benkert","year":"2012","journal-title":"PLoS One."},{"key":"2021022417494907600_i1537-2073-23-1-26-b12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1468-1331.2009.02532.x","article-title":"The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers","volume":"16","author":"Khademi","year":"2009","journal-title":"Eur J Neurol."},{"key":"2021022417494907600_i1537-2073-23-1-26-b13","volume-title":"Common Terminology Criteria for Adverse Events v5.0","author":"National Cancer Institute.","year":"2017"},{"key":"2021022417494907600_i1537-2073-23-1-26-b14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jneuroim.2011.12.009","article-title":"Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab","volume":"243","author":"Mulero","year":"2012","journal-title":"J Neuroimmunol."},{"key":"2021022417494907600_i1537-2073-23-1-26-b15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"key":"2021022417494907600_i1537-2073-23-1-26-b16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"2021022417494907600_i1537-2073-23-1-26-b17","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet."},{"key":"2021022417494907600_i1537-2073-23-1-26-b18","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet."},{"key":"2021022417494907600_i1537-2073-23-1-26-b19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(12)61401-9","article-title":"Breathlessness, night sweats, and weight loss on natalizumab","volume":"380","author":"Dahdaleh","year":"2012","journal-title":"Lancet."},{"key":"2021022417494907600_i1537-2073-23-1-26-b20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12883-016-0635-y","article-title":"Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study","volume":"16","author":"Gold","year":"2016","journal-title":"BMC Neurol."},{"key":"2021022417494907600_i1537-2073-23-1-26-b21","article-title":"Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus","volume":"4","author":"Navas","year":"2018","journal-title":"Mult Scler J Exp Transl Clin."},{"key":"2021022417494907600_i1537-2073-23-1-26-b22","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1586\/14737175.2014.962517","article-title":"How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?","volume":"14","author":"Fragoso","year":"2014","journal-title":"Expert Rev Neurother."},{"key":"2021022417494907600_i1537-2073-23-1-26-b23","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1038\/s41598-018-26519-w","article-title":"Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients","volume":"8","author":"Montes Diaz","year":"2018","journal-title":"Sci Rep."}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/23\/1\/26\/2778718\/i1537-2073-23-1-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/23\/1\/26\/2778718\/i1537-2073-23-1-26.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:12:59Z","timestamp":1752786779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/prevalence-of-latent-tuberculosis-in-the-multiple-sclerosis-clinic-and-effect-of-multiple-sclerosis-treatment-on-tuberculosis-testing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,14]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2019-015","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,14]]}}}